This trial will test the safety of CFI-400945, either alone or in combination with azacitidine or decitabine, in people with blood cancer.
4 Primary · 5 Secondary · Reporting Duration: 36 months
Experimental Treatment
72 Total Participants · 4 Treatment Groups
Primary Treatment: CFI-400945 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: